After hanging up the phone, Gu Xin looked out of the window, hesitating.
At this point, Anxu Pharmaceuticals was in shambles, and the shareholders' confidence had vanished.
When a company could no longer bring profits to its shareholders and was also unable to go public, it might have been on the brink of collapse.
Dongsheng Pharmaceuticals sought to acquire it because they valued Anxu's formulas, the comprehensive experimental base, and the production line.
In fact, facing the onslaught of foreign pharmaceutical companies was already a challenging ordeal for domestic counterparts.
The reforms and opening up were beneficial, but... when a large volume of foreign medicines flooded the Chinese market, if we were capable of fighting back, it was fine; if not...the consequences could be perilous.
The invasion of capital and technology was ruthless.
Anxu Pharmaceuticals was just one among many companies.
This was both a good and a bad thing.
